FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis…
Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to…
Read More...
Read More...
